Notably, our outcomes detected that PRR7-AS1 expression status was inversely correlated with the immune checkpoint genes such as CD274, CTLA4, and PDCD1 in some carcinomas, which implies that cancer patients with high PRR7-AS1 expression status are probably not appropriate for the immune checkpoint inhibitors. The gene discussed is CD274; the disease is carcinoma.